

Journal of Pharmaceutical Research International

33(46B): 555-561, 2021; Article no.JPRI.75742 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759)

Protective Effect of *Blumera lacera* in Rifampicin Induced Hepatotoxicity in Rats

Devendra S. Shirode^{1*}, Bindurani L. G. P. Ram², Gaurav Jain³ and Ashwini Singh⁴

¹Deptartment of Pharmacology, Dr. D. Y. Patil College of Pharmacy, Akurdi, Pune 411044, Maharashtra, India. ²Faculty of Pharmacy, Vishwakarma University, Kondhwa (BK), Pune-411048, Maharashtra, India. ³IES Institute of Pharmacy, Bhopal-462044, Madhya Pradesh, India. ⁴Department of Patanjali Herbal Research, Patanjali Research Institute, Haridwar 249405, Uttarakhand, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i46B32976 <u>Editor(s):</u> (1) Dr. S. Prabhu, Sri Venkateswara College of Engineering, India. <u>Reviewers:</u> (1) Elizabeth B. Umoren, PAMO University of Medical Sciences, Nigeria. (2) Saira Shahnaz, NHU, Pakistan. Complete Peer review History: <u>https://www.sdiarticle4.com/review-history/75742</u>

Original Research Article

Received 10 August 2021 Accepted 16 October 2021 Published 23 October 2021

ABSTRACT

Tuberculosis is one of the bacterial infection caused by mycobacterium tuberculosis strain and the treatment for it involves the use of anti-tubercular drugs. Rifampicin is one of the common drug that is used for tuberculosis but it potentiates liver toxicity due to metabolism. Objective: The present study was designed to Check the a hepatoprotective agent from a natural source. The natural source was chosen to minimize the side effects that occur due to conventional or synthetic drugs. The hepatoprotective activity of 70% ethanol extract of *Blumea lacera* leaves (EEBLL) was evaluated against Rifampicin induced hepatotoxicity in rats. Preliminary phytochemical screening, acute oral toxicity, *in vivo* antioxidant activity, physical and Biochemical parameters were evaluated for hepatoprotective activity. Preliminary phytochemical screening revealed that flavonoids, tannin and saponins are present in EEBLL. Acute oral toxicity was performed as per the Organization for Economic Co-operation and Development (OECD) guidelines and selected doses of 200 and 400 mg/kg. In rifampicin induced hepatotoxicity in rats, the effect of EEBLL on the biochemical

*Corresponding author: E-mail: devendrashirode@dyppharmaakurdi.ac.in, dssdypcop@gmail.com;

parameters (SGOT, SGPT, ALP, direct and total Bilirubin) was assessed. The increased levels of the above-mentioned biochemical indicators of hepatotoxicity were significantly normalized after the pretreatment with EEBLL (200 mg/ kg and 400mg/kg). The histopathological studies also supported above findings. It is concluded from this study that EEBLL possesses hepatoprotective properties which may be attributed to the polyphenolic compounds that are present in the plant. Further isolation and characterization are required to identify the potent compound as hepatoprotective.

Keywords: Hepatoprotective activity; Blumea lacera; rifampicin; biochemical parameters.

1. INTRODUCTION

Rifampicin is the first line drug to treat tuberculosis (TB) due to its efficacy, but its major adverse effects cause liver diseases [1]. Liver diseases include cirrhosis. viral hepatitis. hepatocellular carcinoma and alcohol-associated liver disease etc., are responsible for approximately 2 million deaths every year. Obesity, diabetes, viral hepatitis and druginduced hepatotoxicity are also a major concern. Liver transplantation creates a financial burden. To overcome the major adverse effect of rifampicin and other drugs induced liver damage, available conventional or synthetic hepatoprotective drugs are sometimes insufficient and may induce adverse effects. In view to develop potent hepatoprotective agent from natural source against rifampicin induced hepatotoxicity in albino rats, the efficacy of Blumea lacera was investigated in rats.

Blumea lacera belongs to the family Asteraceae. It has terpentine odour [2] and upto 0.9 m height with ash coloured [3]. As per the literature survey, it is astringent, expectorant, thermogenic, ophthalmic, antipyretic, digestive, febrifuge, anthelmintic, liver tonic and stimulant [4]. The aerial parts of plant were used to isolate the campesterol [5]. Recent studies have shown antimicrobial [4], analgesic [5] and antiulcer activity [6]. Our literature survey revealed that the hepatoprotective activity of EEBLL was not investigated; hence these activities have been investigated in the present study.

2. MATERIALS AND METHODS

2.1 Plant Material and Preparation of EEBLL

The plant material was collected from the area of sudumbare, Pune and it was authenticated by Botanist Professor Dr. S. S. Deokule, Savtribhai Phule Pune University, Pune. Plant material was shade dried under dark condition and at room temperature. It was pulverized and subjected to soxhlet extraction process using petroleum ether, chloroform and ethanol. Preliminary phytochemical analysis revealed the presence of saponins, steroids and flavonoids in Ethanol Extract of *Blumea lacera* leaves (EEBLL).

2.2 Animals

Mice weighted (18-25 g) and Wistar albino rats (150-220 g) were used.

2.3 Acute Toxicity Studies

Albino mice were used for the acute oral toxicity as per OECD Guideline no 420 given by CPCSEA [7].

2.4 Experimental Designs [8,9]

The animals were divided into five groups of six animals each.

Group I: Normal control group - The animals in this group received distilled water (1 ml/100 gm, p.o.) as vehicle. Group II: Positive control (toxic) group - The animals in this group received rifampicin (1 gm/kg, p.o. in 5 % gum acacia) at day one. Group III: Standard group - The animals in this group received rifampicin (1 gm/kg, p.o. in 5 % gum acacia) at day one, and after 30 min. Silymarin (100 mg/kg, p.o.) was administrated. Group IV: EEBLL group - The animals in this group received rifampicin (1 gm/kg, p.o. in 5 % gum acacia) at day one, after 30 min. EEBLL (200 mg/kg p.o.) was administered Group V: EEBLL Group - The animals in this group received rifampicin (1 gm/kg, p.o. in 5 % gum acacia) at day one, after 30 min. EEBLL (400 mg/kg p.o.) was administered.

On the 2nd day, blood was withdrawn from all the animals using retro-orbital plexus method and centrifuged the blood at 2000 rpm for 10 minutes.

Collected serum was used to analyze the SGPT [10], SGOT [11], ALP [12], Bilirubin (total and direct) [13] parameters. The liver was isolated from all the animals and subjected for estimation of physical parameters (wet liver weight, liver volume), *in vivo* Antioxidant parameters (GSH and LPO) and histopathological investigations.

2.4.1 In vivo tissue GSH estimation [14]

Liver tissue sample was added in ice cold trichloroacetic acid (1gm tissue in 10 ml 10% TCA) and homogenized using an ultra trux tissue homogenizer. The homogenized mixture was centrifuged at 3000 rpm for 10 minutes. Collected supernatant (0.5 ml) was added in 2ml of (0.3M) disodium hydrogen phosphate solution. The absorbance of solution was measured at 412 nm after addition of 0.2 ml dithiobisnitrobenzoate (0.4 mg/ml in 1% sodium acetate) (Fig. 3).

2.4.2 *In vivo* lipid peroxidation estimation [15]

The biological sample (0.1-2.0 mg of membrane protein or 0.1-2.0 µmol of lipid phosphate) of liver tissue was prepared. The 1.0 ml of prepared biological sample was mixed with 2.0 ml TCA-TBA-HCL solution and heated for 1 hour. The solution was centrifuged at 1000 rpm for 10 minutes and supernatant was collected to determine the absorbance at 535 nm (Fig. 4).

2.5 Statistical Analysis

(1ml dist. water p.o.)

(intoxicated) (1ml dist.

waterp.o.+1gm/kg p.o.) Rifampicin + Silymarin

p.o.+ 200mg/kg p.o.)

p.o.+ 400mg/kg p.o.)

(1 gm/kg p.o. + 100 mg/kg,

Rifampicin + EEBLL (1 gm/kg

Rifampicin + EEBLL (1 gm/kg

Rifampicin control

p.o.)

Results were expressed as mean \pm SEM (n=6). For statistical analysis, Graph Pad Instat Software was used using one way analysis of variance (ANOVA) and Tukey-Kramer Multiple Comparisons Test. For statistical significance P value less than 0.05 was considered to be ideal.

3. RESULTS AND DISCUSSION

Administered Rifampicin is metabolized to active compound diacetyl rifampicin. It binds to RNA polymerase and thereby inhibit the synthesis of RNA. This causes cirrhosis and acute hepatic failure. Which is evidenced by the increased level of some serum enzymes [8,16].

In the rifampicin induced hepatotoxicity rats, liver cells were damaged as indicated by increased levels of SGOT and SGPT in serum [17]. Alkaline phosphatase (ALP) is the prototype of these enzymes that are released unequally [18] and reflected in the pathological phenomenon in biliary flow [19]. Serum bilirubin content was also elevated in the Rifampicin induced liver toxicity in rats.

The rifampicin treated animals showed significant (p<0.01) increase in the level of SGPT, SGOT, ALP, Bilirubin, wet liver weight, liver volume, liver peroxide content (LPO) and a significantly (p<0.01) decreased tissue glutathione (GSH), when compared with animals in the normal group. EEBLL treated animals showed significant (p<0.01) recovery in liver architecture in all the parameters (Table 1). Histopathological observations also supported these findings (Fig. 5).

0.026

 $2.56 \pm$

0.216

 $0.728 \pm$

0.635±

0.04***

0.727±

0.053***

0.037***

0.019

0.06

 $0.2 \pm$

0.09***

0.177±

0.01***

0.208±

0.02***

1.485 ±

Treatment	Biochemical parameters (Mean ± SEM)				
	SGOT IU/L	SGPT IU/L	ALP IU/L	Total bilirubin mg/dl	Direct bilirubin mg/dl
Normal control	90 ±	59 ±	116.5 ±	0.62 ±	0.19 ±

5.26

 $693 \pm$

79.38

110±

154±

219±

10.47***

33.34***

7.30***

13.576

680.17

±24.89

 $190.16 \pm$

7.29***

430.67±

25.5***

563.17±

10.94**

5.10

619 ±

29.57

 $145 \pm$

6.875***

389.83±

16.93***

375.67±

22.32***

Significance ***P<0.001, **P<0.01, *P<0.05, ^{ns}P>0.05, compared to rifampicin treatment

Shirode et al.; JPRI, 33(46B): 555-561, 2021; Article no.JPRI.75742




Fig. 1. Effect of EEBLL on liver volume level in rifampicin induced hepatotoxicity









Fig. 2. Effect of EEBLL on liver weight level in rifampicin induced hepatotoxicity in rat














Group I (Normal control) Normal hepatic globular structure. Normal central vein and portal tract




Group III (RFM + Std drug silymarin 100 mg/kg) Normal liver architecture. Minimal degeneration of hepatocytes and sinusoidal congestion



Group II (RFM control 1 g/kg p.o.) Severe necrosis of hepatocytes. Disturbed liver architecture. Infiltration of inflammatory cells. Congestion of sinusoids



Group IV (RFM + EEBLL 200 mg/kg p.o.) Mild sinusoidal congestion and NAD (not other abnormality detected)



Group V (EEBLL 400 mg/kg, p.o.) Minimal sinusoidal congestion and NAD (not other abnormality detected)

Fig. 5. Histopathological studies of liver architecture (H & E 40X)

In the rifampicin induced hepatotoxicity in rats, EEBLL exhibited hepatoprotective properties that may be due to inhibition of the active metabolite formation leading to a reduction in the drug metabolizing enzymes. The EEBLL showed significant (p<0.01) reduction in the above mentioned biochemical markers, which suggest the stability of the biliary functions and a sign of regeneration process of liver.

4. CONCLUSION

It can be concluded that administrated EEBLL exhibited hepatoprotective property in rifampicin

induced liver damage in rats. This may be due to the presence of steroids, flavonoids, saponins and antioxidant properties in the EEBLL. Isolation, characterization, formulation and screening of bioactive compounds are planned and projected for further studies.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

Protocol for Animal activity was approved from the institutional animal ethical committee (1554/PO/a/11/CPCSEA) for preclinical screening.

ACKNOWLEDGEMENTS

The authors are thankful to Dr. D. Y. Patil college of Pharmacy, Akurdi, Pune for providing all the facilities to carry out this research work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- 1. Yew WW, Leung CC. Anti-tuberculosis drugs and hepatotoxicity. Respirology. 2006;11:1599-604.
- 2. Varier PSV. Indian Medicinal Plants. Arya Vaidyasala Kottakkal, Orient Longman. 1995;278.
- 3. Kirtikar KR, Basu BD. Indian Medicinal Plants. International Book distribution, Dehradun. 2003;1340
- 4. Singh B, Singh S, Singh Surendra, Ali L, Mahajan R. Ethanobotanical significance and antimicrobial activity

of *Blumea lacera*. IJPBA. 2010;1(3): 314-6.

- Rastogi RP, Mehrotra BN. Compendium of Indian medicinal plants, CDRI Lucknow & NISC New Delhi. 1999;102.
- Shirode DS, Powar PV, Jain BB, Agarwal A. Antiulcer effect of *Blumea lacera* against Gastric ulcers in rats. Research J Pharm and Tech. 2020;13(7): 3340-2.
- 7. Veeraraghavan P. Expert consultant, CPCSEA, OECD guideline No. 420; 2000.
- 8. Bafna AR, Mishra SH. Effect of methanolic extract of *Achyranthes aspera* Linn. On rifampicin induced hepatotoxicity in rats. Ars Pharm. 2004;45(4):343-51.
- Kulkarni AS, Siraskar BD, Deshpande AD, Kulkarni AV, Dhounde SM. Study of hepatoprotective activity of *Portulaca oleracea* L. on rifampicin induced hepatotoxicity in rat. The pharmacist. 2007;2(2):1-5.
- Bradley DW, Maynard JE, Emery G, Webster H. Transminase activity in serum of long term hemolysis patients. Clin Chem. 2003;18:1442.
- 11. Rej R, Fasce CF, Vanderlinde RE. Increased aspartase aminotransferase activity of serum after in vitro supplymentation with pyridoxal phosphate. Clin Chem. 1973;19:92.
- 12. McComb RB. Bowers GN. Study of optimum buffer conditions for measuring alkaline phosphatase activity in human serum. Clin Chem. 1972;18:97.
- 13. Pearlman PC, Lee RT. Detection of measurement of total Bilirubin in serum with use of surfactants as solubilizing agents. Clin Chem. 1974;20:447.
- 14. Aykae GM, Vysal AS, Yalein TN, Kocak AS, Oz H. The effect of chronic ethanol ingestion on hepatic lipid peroxide, Glutathione, glutathione peroxidase and glutathione transferase in rats. Toxicology. 1985;36:71-6.
- Buege AJ, Steven AD. Microsomal lipid peroxidation. London: Moury Kleiman Co. 1978;302.
- Shankar MB, Parikh JR, Geetha M, Mehta RS, Saulija AK. Hepatoprotective activity of a benzopyrone from *Tephrosia purpurea* pers. Journal of Natural Remedies. 2005; 5(2):115-20.
- 17. Drotman RB, Lowhorn GT. Serum enzymes as indicators of chemical induced

liver damage. Drug Chemical Toxicology. 1978;1:163–71.

- Szczeklik E, Orlowski M, Szewes A. Serum gamma glutamyl peptidase activity in liver disease. Gastroenterology. 1961; 41:353-9.
- Ploa GL, Hewitt WR. Detection and evaluation of chemically induced liver injury. In: Wallace Hayes A., (Ed.), Principles and Methods of Toxicology. 2nd ed. Raven Press, New York 1989;399– 628.

© 2021 Shirode et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle4.com/review-history/75742